
Inari Medical NARI
Quarterly report 2024-Q3
added 10-28-2024
Inari Medical Book Value 2011-2026 | NARI
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Inari Medical
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 417 M | 239 M | 200 M | -39.1 M | -39.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 417 M | -39.4 M | 156 M |
Quarterly Book Value Inari Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 435 M | 424 M | 447 M | 465 M | 452 M | 436 M | 427 M | 417 M | 415 M | - | 419 M | 239 M | 234 M | 222 M | 214 M | 200 M | 200 M | 200 M | 200 M | 15 M | 15 M | 15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 465 M | 15 M | 290 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 13.11 | 0.23 % | $ 1.77 B | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
43.2 M | $ 25.71 | 2.43 % | $ 217 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
EDAP TMS S.A.
EDAP
|
50.1 M | $ 3.32 | 0.3 % | $ 124 M | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 11.18 | 8.12 % | $ 317 M | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 2.04 | 3.03 % | $ 1.24 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.61 | -4.04 % | $ 38 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 56.14 | 5.11 % | $ 1.65 B | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.03 | - | $ 17.4 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 60.1 | 2.0 % | $ 3.28 B | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 15.06 | 2.87 % | $ 353 M | ||
|
Butterfly Network
BFLY
|
169 M | $ 4.79 | -2.64 % | $ 1.01 B | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 90.18 | 2.72 % | $ 12.2 B | ||
|
Delcath Systems
DCTH
|
111 M | $ 10.38 | 1.67 % | $ 372 M | ||
|
NanoVibronix
NAOV
|
33.5 M | - | - | $ 1.08 M | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 36.66 | 1.95 % | $ 1.14 B | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 88.51 | 5.78 % | $ 3.07 B | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 83.5 | 2.81 % | $ 48.8 B | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.23 | -2.97 % | $ 62.5 M | ||
|
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.28 | 6.67 % | $ 52.1 M | ||
|
MiMedx Group
MDXG
|
257 M | $ 3.36 | 8.91 % | $ 497 M | ||
|
Myomo
MYO
|
11.4 M | $ 0.86 | 8.54 % | $ 36 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
231 M | - | - | $ 217 M | ||
|
Natus Medical Incorporated
NTUS
|
425 M | - | 1.94 % | $ 1.05 B |